Sun Pharma-Ranbaxy Deal Has Some Important Lessons

Over the last few days, media has been abuzz with the news of Sun Pharma’s $4-billion acquisition of Ranbaxy.

Given the fact that it is the second largest acquisition in the Indian pharmaceutical sector till date, it is not surprising that everybody is fixated on the sheer size of the deal.

But if you look beyond the fancy valuation, this courageous move by Sun Pharma founder Diliip Shanghvi to buy out the beleaguered Ranbaxy from Daiichi Sankyo has some important lessons for everybody.

1. Creating value

Dilip Shanghvi, a first-generation entrepreneur, has not rested on his laurels after building India’s most valuable pharmaceutical company.

By acquiring Ranbaxy, Sun Pharma has taken a giant leap to emerge as the fifth largest speciality generic drug maker globally and the largest in India.

An entity that started off with a single manufacturing plant in 1983 is now poised to have operations in 65 countries, 47 manufacturing facilities across five continents and a global portfolio of specialty and generic products once the Ranbaxy deal closes.

Not only that, Sun Pharma’s revenue will almost double to $4.3 billion.

2. Restoring lost glory

Ranbaxy’s acquisition by Sun Pharma will result in a formidable generics power house, which could help restore India’s reputation as a reliable provider of good quality, affordable medicines for patients the world over.

Having successfully dealt with regulatory issues at its US subsidiary Caraco Pharmaceuticals, I believe Sun Pharma is better placed than Ranbaxy’s erstwhile Japanese owners in tackling the various instances of regulatory non-compliance in the company.

Both Sun Pharma and Ranbaxy have formidable track records in the US market, so the pooling of their manufacturing, distribution and regulatory strengths could be a crucial step forward in regaining the market share the Indian pharma industry has lost in the aftermath of the recent quality controversy.

3. Living up to reputation

Dilip has an enviable reputation of acquiring distressed assets and turning them around.

He has previously succeeded in reviving the fortunes of Israel-based Taro Pharmaceutical.

If Dilip can give Ranbaxy a fresh lease of life, it will cement his reputation as a turnaround artist par excellence.

4. Unshackling pharma M&As

The Sun Pharma-Ranbaxy deal also shows that there is no need to ring fence the Indian pharma industry though restrictive FDI policies. The domestic pharma industry can compete with pharma MNCs when it comes to M&As.

As an Economic Times editorial put it succinctly: “The current deal shows that what MNCs can do, Indian companies can do as well, to achieve scale.”

The Sun-Ranbaxy merger stands a better chance of being successful due to the inherent similarity of their business models and work cultures.

The Ranbaxy deal has been structured in such a way that Daiichi Sankyo will become thesecond largest shareholder in Sun Pharma. Instead of seeing Daiichi Sankyo as a threat, Dilip sees the Japanese company as an ally in realizing Sun Pharma’s global ambitions.

Depending on the business imperatives, founders of pharma companies should be free to monetize their assets just like most of the other sectors.

5. Doing things differently

Where others had written off Ranbaxy because of the company’s quality and regulatory non-compliance problems in the US, Sun Pharma decided to take a contrarian view.

In fact, Sun Pharma has succeeded in being an outlier in the Indian pharma industry because of Dilip’s penchant of doing things differently.

If there’s one big lesson that a budding entrepreneur can take away from the Sun Pharma-Ranbaxy deal it is that good entrepreneurs need to constantly look for opportunities, whether they are just getting started or already in business. And when opportunities come, one will need to take a calculated risk.

Top 10 Pharmaceutical Companies In India

In the list of top pharmaceutical companies in India it is not the Indian companies but also the MNCs that are becoming the part of the race. Indian pharmaceutical market in 2008 was $7,743m and if compared to year 2007 it was 4% more than that. It is expected that Indian pharmaceutical market will grow more than the global pharmaceutical market and will become $15,490 million in 2014.

 

Top 10 Pharma Companies in India

In the list of top pharmaceutical companies in India it is not the Indian companies but also the MNCs that arebecoming the part of the race. Indian pharmaceutical market in 2008 was $7,743m and if compared to year 2007 it was 4% more than that. It is expected that Indian pharmaceutical market will grow more than the globalpharmaceutical market and will become $15,490 million in 2014. Today Indian pharmaceutical industry is the second most fastest growing industry displaying the revenue of Rs 25,196.48 crore and growth of 27.32 percent. Top pharmaceutical companies in India are also acquiring the small companies worldwide to further expand the market. Pharmaceutical drugs injections, tablets, capsules, syrups are the products of pharma companies in India along with many more.

Looking back into history reveals that it was in 1930 when the first pharmaceutical company in India came into existence in Kolkatta. It is called the “Bengal Chemicals and Pharmaceutical Works”. This Indian company is still there and today it is the part of five drug manufacturing companies that are owned by the government. Till the period of 60 years the pharmaceutical industry in India was overshadowed by the foreign drugmanufacturing companies but with the Patent Act in 1970, the whole scenario of pharmaceutical companies in India had changed since then. With this the Indian market was more open to Indian pharmaceutical companiesthan the MNCs. So with this pharmaceutical companies in India started to grow in number

At present there is a cut throat competition among top pharmaceutical companies in India with the native as well as MNCs. But there are certain issues that are concerning the growth of pharma companies in India. These are:

  • Mandatory licensing and failure of new paten system.
  • Regular power cuts and inadequate infrastructure.
  • Restricted funding.
  • Regulatory hindrances that lead to the delays in the launch of new drug or pharma product.
  • Too many small as well as big pharmaceutical companies and excessive competition.

 

1.Ranbaxy Laboratories Limited

Company Profile

Ranbaxy Laboratories Limited (Ranbaxy), India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 43 countries, world-class manufacturing facilities in 8 countries and serves customers in over 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.

Ranbaxy was incorporated in 1961 and went public in 1973.
Corporate Office
Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: 91- 124- 4135000
Fax: 91-124-4135001

Registered Office
A-41, Industrial Area Phase VIII-A,
Sahibzada Ajit Singh Nagar,
Mohali – 160 071 (Punjab), INDIA

2.Dr.Reddy’s Laboratories Ltd

Dr. Reddy’s originally launched in 1984 producing genericmedications. In 1986, Reddy’s started operations on branded formulations.Within a year Reddy’s had launched Norilet, the company’s first recognizedbrand in India. Soon, Reddy’s obtained another success with Omez, its brandedomeprazole – ulcer and reflux oesophagitis medication – launched at half theprice of other brands on the Indian market at that time.

Within a year, Reddy’s became the first Indian company toexport the active ingredients for pharmaceuticals to Europe. In 1987, Reddy’sstarted to transform itself from a supplier of pharmaceutical ingredients toother manufacturers into a manufacturer of pharmaceutical products.

HR Contact

Human Resources 
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3
Banjara Hills, Hyderabad
Hyderabad – 500 034
INDIA

Email: talent@drreddys.com

Visit :alumni.drreddys.com

Dr. Reddy’s Laboratories Ltd.
6-3-1192/1/1 Whitehouse,
Block 3, 5 Floor,
Kundanbagh,
Begumpet,
HYDERABAD 500 016 India
Tel: 040-5502 2500
Website: http://www.drreddys.com

 

3.Cipla Pharmaceuticals Limited

History:

Khwaja Abdul Hamied, the founder of Cipla, was born on October 31, 1898. The fire of nationalism was kindled in him when he was 15 as he witnessed a wanton act of colonial highhandedness. The fire was to blaze within him right through his life.

In college, he found Chemistry fascinating. He set sail for Europe in 1924 and got admission in Berlin University as a research student of “The Technology of Barium Compounds”. He earned his doctorate three years later.

In October 1927, during the long voyage from Europe to India, he drew up great plans for the future. He wrote: “No modern industry could have been possible without the help of such centres of research work where men are engaged in compelling nature to yield her secrets to the ruthless search of an investigating chemist.” His plan found many supporters but no financiers. However, Dr Hamied was determined to being “a small wheel, no matter how small, than be a cog in a big wheel.”

Cipla is born

In 1935, he set up The Chemical, Industrial & Pharmaceutical Laboratories, which came to be popularly known as Cipla. He gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs.

The search for suitable premises ended at 289, Bellasis Road (the present corporate office) where a small bungalow with a few rooms was taken on lease for 20 years for Rs 350 a month.

Mahatma Gandhi visits Cipla
Mahatma Gandhi visits Cipla (July 4th 1939)

July 4, 1939 was a red-letter day for Cipla, when the Father of the Nation, Mahatma Gandhi, honoured the factory with a visit. He was “delighted to visit this Indian enterprise”, he noted later. From the time Cipla came to the aid of the nation gasping for essential medicines during the Second World War, the company has been among the leaders in the pharmaceutical industry in India.

On October 31, 1939, the books showed an alltime high loss of Rs 67,935. That was the last time the company ever recorded a deficit.

In 1942, Dr Hamied’s blueprint for a technical industrial research institute was accepted by the government and led to the birth of the Council of Scientific and Industrial Research (CSIR), which is today the apex research body in the country.

In 1944, the company bought the premises at Bombay Central and decided to put up a “first class modern pharmaceutical works and laboratory.” It was also decided to acquire land and buildings at Vikhroli. With severe import restrictions hampering production, the company decided to commence manufacturing the basic chemicals required for pharmaceuticals.

In 1946, Cipla’s product for hypertension, Serpinoid , was exported to the American Roland Corporation, to the tune of Rs 8 lakhs. Five years later, the company entered into an agreement with a Swiss firm for manufacturing foromycene.

Dr Yusuf Hamied, the founder’s son, returned with a doctorate in chemistry from Cambridge and joined Cipla as an officer in charge of research and development in 1960.

In 1961, the Vikhroli factory started manufacturing diosgenin. This heralded the manufacture of several steroids and hormones derived from diosgenin.

The founder passes away

The whole of Cipla was plunged into gloom on June 23, 1972 when Dr K A Hamied passed away. The Free Press Journal mourned the death of a “true nationalist, scientist and great soul…. The best homage we can pay to him is to contribute our best in the cause of self-reliance and the prosperity of our country in our fields of endeavour.”

Corporate Office Address:

Cipla Ltd.
Mumbai Central
Mumbai 400 008
India

Telephone:
91 22 2308 2891
91 22 2309 5521

Fax:
91 22 2307 0013
91 22 2307 0393

 

4.Sum Pharmaceutical Industries Ltd.

PROFILE

We are an international speciality pharma company, with a large presence in the US and India,  and a footprint across  41 other markets.

In the US, which is our largest market, we have built a strong  pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio.

In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India.

We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th  largest by prescription sales, a  rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012)

Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics.

HISTORY

Sun Pharma began in 1983 with just 5 products to treat psychiatry ailments. Sales were initially limited to two states in Eastern India. Sales were rolled out natiowide in 1985. Products for cardiology were introduced in 1987, and Monotrate, one of the first products launched then, countinues to be sold even today. Important products in Cardiology were later added; several of these introduced for the first time in India, and these brought patients the latest treatments at a sensible cost, a belief we’ve always lived by.

Realizing the fact that research is a critical growth driver, we established our  first research center, SPARC, in 1993 and this created the base for strong product and process development that enabled growth in the subsequent years.

Sun Pharma was listed on the main stock exchanges in India in 1994; and the Rs. 55 crore issue of a Rs. 10 face value equity share offered at a premium of Rs. 140/-, was oversubscribed 55 times. The minimum 25% that was required under the regulations then for listing was offered to the public, the founder’s family continues to hold a majority stake in Sun Pharma.

We used this money to build a greenfield site for API manufacture, as well as for acquisitions. For allowed acquisitions, typically companies or assets that allowed us entry into a new market or therapy area, assets that could be turned around and  brought on track were identified.

Our first API manufacturing plant was built in Panoli in 1995, for access to high quality actives ahead of competition, and in order to tap the vast international opportunity for speciality APIs.

Another API plant, our Ahmednagar plant, was acquired from the multinational Knoll Pharmaceuticals in 1996, and expanded and substantially upgraded for regulated markets, with capacity addition over the years across differentiated API lines such as anticancers and peptides. This was the first several sensibly priced acquisitions, each of which would bring important parts to our long-term strategy.

In 1997, our headquarters shifted to Mumbai, India’s commercial capital. We began the first of our international acquisitions with an initial $7.5 million investment in Caraco, Detroit. By 2000, we had completed 8 acquisitions, each such move adding new therapy areas or offering an entry to important international markets. A new research center was set up in Mumbai for generic product development for the US market. In India, as new therapy areas were entered into post acquisition; customer attention, product selection and focused marketing helped us gain a foothold in areas like orthopedics, gynecology, oncology, etc. From a ranking at 38th in 1994, by 2000 we were ranked 5th with a leadership in 8 of the 11 therapy areas that we are present in. The year 2000 was the year of turnaround at the US subsidiary, Caraco, as it began to receive approvals after successful inspection by the USFDA.

In December 2004, a research center spread over 16 acres was inaugurated by the President of India, with special lab space for drug discovery and innovation. The post 2005 years have witnessed important acquisitions to strengthen our US business- the purchase of manufacturing assets for controlled substances in Cranbury,NJ; that of a site to make creams and lotions in Bryan, that of Alkaloida, a Hungary based API and dosage form manufacturer , and, Chattem Ltd., a Tennessee-based controlled substance API manufacturer.

In September 2010 acquisition of Taro Pharmaceuticals doubled the size of our US business and brought us a range of generics including a strong line of dermatologicals. Taro’s manufacturing facilities in Israel and Canada substantially add to our production capacity.

The tally at the end of 2011:
23 manufacturing plants in 3 continents
12000  employees
4 World class research centers
Brand in markets worldwide
A strong presence in the US generic market
Increasing research investments
Over 60% of sales from international markets

ADDRESSES EU Contacts

Corporate Office   

Sun Pharma     

Acme Plaza,
Andheri – Kurla Rd, Andheri (E),
Mumbai – 400 059.

5. Lupin Pharmaceutical Ltd.

Who We Are

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top five pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.

Lupin Limited, headquartered in Mumbai, India, is strongly research focused. It has a program for developing New Chemical Entities. The company has a state-of-the-art R&D center in Pune and is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (ACE-inhibitors and cholesterol reducing agents) and has a notable presence in the areas of diabetes, anti-inflammatory and respiratory therapy.

We are building on our parent company’s strengths of vertical integration in discovery research, process chemistry, active pharmaceutical ingredient production, formulation development and regulatory filings. Lupin Pharmaceuticals, Inc. is committed to achieving its vision and mission of becoming an innovation led transnational pharmaceutical company.

Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc. says “founded on the strengths of our parent company Lupin Limited, Lupin Pharmaceuticals, Inc. intends to bring a portfolio of generics as well as branded products to the US market.”

For the financial year ended March 2010, Lupin Limited’s Revenues and Profit after Tax were Rs.47,678 million (US$ 1.1 billion) and Rs.6,186 million (US$ 152 million) respectively. Please visit http://www.lupinworld.com for more information about Lupin Limited.

The Lupin Story

The company was named after the Lupin flower because of the inherent qualities of the flower and what it personifies and stands for. The Lupin flower is known to nourish the land, the very soil it grows in. The Lupin flower is also known to be tolerant of infertile soils and capable of pioneering change in barren and poor climes. The Lupin flower and bean pods have also long been used as food and sources of nourishment, thus protecting and nurturing life.

Embedded inLupin was a formula for growth. Forty-four years on, what has stayed with us is that same entrepreneurial spirit, culture of creativity and innovation and pride in belonging to an industry that makes a difference in the lives of people.

We are today a fully integrated pharmaceutical company with an unrivaled position in the US, India and Japan. This position is built on a backbone of cutting-edge research, world-class manufacturing facilities and a truly global supply chain. With the building blocks in place, the future looks brighter than its ever been. We are Built to Grow.

Built to Grow

Lupin is poised and ready for its future. We have all the elements in place to play a major role in the global pharmaceutical landscape and to continue our mission of delivering consistent high growth in revenues, margins and returns for our Company and its stakeholders.

Our culture of growth is built upon trust and transparency in all our dealings and in all our relationships. Be those relationships with our customers, our investor communities, our people or society at large. We are proud to be part of an industry that can make a real difference to people’s lives. We now stand ready to grasp opportunities emerging in a new world. Global economies are going though challenging times. Over our 44-year history we have been through such cycles before and we have learnt that a firm foundation, a passionate growth ethic embedded in a sound business strategy, underpinned by a strong balance sheet are the essentials for success.

A thirst for growth has been the common thread binding us with our heritage. But for us, growth is not just the numbers; it is our part in enhancing the knowledge, experience and talent of our people that we value and nurture. We are an agile organization, working as a global team, creating and unlocking value. Lupin is Built as One, Built to Enrich.

Corporate Overview

Headquartered in Mumbai, India, Lupin Limited today is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.

Dr. Desh Bandhu Gupta’s vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic pharmaceutical companies globally.

Lupin first gained recognition when it became one of the world’s largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments. The Company’s R&D endeavours have resulted in significant progress in its NCE program. The Company’s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin’s world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realize its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan’s MHLW, TGA Australia, WHO, and the MCC South Africa.

Our Drugs and products reach over 70 countries in the world. Today, Lupin has emerged as the 5th largest and the fastest growing Top 5 company in the U.S (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS) and the fastest growing top 10 Generic players in Japan and South Africa. (IMS), Today, Lupin also has the unique distinction of being the fastest growing top 10 Generics players in the two largest pharmaceutical markets of the world – The U.S (ranked 5th by prescriptions & growing at 52 %) and Japan (ranked 7th and growing at 23%). Lupin’s Consolidated Revenues and Profit after Tax were Rs. 57,068 million and Rs. 8,626 million for FY 2010-11.

Going forward, our research backbone, best-in-class class manufacturing capabilities, marketing and servicing depth globally will stand us in good stead. The company will continue to focus on identifying and developing niche segments, a differentiated product portfolio in all its chosen markets backed up by strategic partnerships and in-licensing, and investment in new areas such as biosimilars – well on-course to becoming a global pharmaceutical powerhouse.

 

6.Aurobindo Pharma Limited

Overview
Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry.

Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.

Through cost effective manufacturing capabilities and a few loyal customers, the company entered the high margin specialty generic formulations segment. In less than a decade Aurobindo Pharma today has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries.

The formulation business is systematically organized with a divisional structure, and has a focused team for key international markets. Leveraging on its large manufacturing infrastructure for APIs and formulations, wide and diversified basket of products and confidence of its customers, it aims to achieve USD 2 billion revenues by 2015-16. Aurobindo’s nine units for APIs / intermediates and seven units for formulations are designed to meet the requirements of both advanced as well as emerging market opportunities.

A well integrated pharma company, Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations. Our customers include premium multi-national companies.. With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs from India.

Indian 
Indian Subsidiaries:
APL Healthcare Limited
Plot No.2, Maitrivihar
Ameerpet
Hyderabad – 500 038.
Tel: +91 40 66725333
Contact Person: Mr. A. Mohan Rami Reddy
E-mail: cs@aurobindo.com
APL Research Centre Limited
Plot No.2, Maitrivihar
Ameerpet
Hyderabad – 500 038
Tel: +91 40 66725333
Contact Person: Mr. A. Mohan Rami Reddy
E-mail: cs@aurobindo.com

7.GlaxoSmithKline Pharmaceuticals Ltd.

About GSK – Our company

Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 4000 people. Globally, we are a £ 27.4 billion, leading, research-based healthcare and pharmaceutical company. In India, we are one of the market leaders with a turnover of Rs. 2275 crore and a share of 3.9%*. At GSK, our mission is to improve the quality of life by enabling people to do more, feel better and live longer. This mission drives us to make a real difference to the lives of millions of people with our commitment to effective healthcare solutions.

The GSK India product portfolio includes prescription medicines and vaccines. Our prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The company is the market leader in most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia and others.

With opportunities in India opening up, GSK India is aligning itself with the parent company in areas such as clinical trials, clinical data management, global pack management, sourcing raw material and support for business processes including analytics.

GSK’s best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company’s products are readily available across the nation. GSK has two manufacturing units in India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The state of art plant at Nashik makes formulations.

Being a leader brings responsibility towards the communities in which we operate. At GSK, we have a Corporate Social Responsibility program that works towards fulfilling basic healthcare, education and other developmental needs of the underserved population. With this dedication and commitment, we believe that the world will be better, healthier and happier.

GSK is committed to developing new and effective healthcare solutions. The values on which the group was founded have always inspired growth and will continue to do so in times to come.

 

8.Cadila Pharmaceuticals Limited

We are one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. As an integrated healthcare solutions provider, we cater to over 45 therapeutic areas. With presence in over 90 countries, we focus on providing high quality, affordable treatment.

We have one of the best Research and Development setups in India, which forms the backbone of our state-of-the-art manufacturing facilities – conforming to the most stringent international cGMP norms – at Dholka, Ankleshwar, Kadi and Hirapur in Gujarat; Samba in Jammu & Kashmir; and Addis Ababa in Ethiopia.

Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the state of Gujarat. Over the last five decades, it has been developing and manufacturing pharmaceutical products and selling and distributing these in over 50 countries around the world. An integrated healthcare solutions provider with pharmaceutical product basket, it caters to over 45 therapeutic areas that include cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. The company focuses on providing high quality, appropriately priced products to its customers and supports all these with dedicated customer service. Cadila Pharmaceuticals has a multicultural, multilingual and multinational workforce of more than four thousand employees including over two hundred people outside India in forty-nine countries of Africa, CIS, Japan and USA.

The company has one of the best Research and Development (R&D) setups in India, manned by more than three hundred and fifty scientists and engineers from various disciplines including biology, pharmacology, clinical research, chemistry, toxicology, phytochemistry and different disciplines of engineering. The company also participates in Public-Private partnerships for developing diagnostic, preventive and curative pharmaceutical and diagnostic products.

Cadila Pharmaceuticals is the first Indian company to get IND approval by USFDA for clinical trials to be conducted in India. Subsequently, the company has filed four more INDs with USFDA. Of the five INDs filed, one is for pulmonary tuberculosis; the trial is supported by Department of Biotechnology, Govt. of India. The remaining four are for various types of cancers, e.g., Lung Cancer, Prostrate cancer, Bladder Cancer and Melanoma. Thus all the INDs are for providing solutions to major global health care problems. The clinical trials on Prostrate cancer, Lung cancer and Bladder cancer are supported by Department of Science and Technology to encourage innovations.

The company has state-of-the-art manufacturing facilities conforming to the most stringent international cGMP norms vis-à-vis WHO-GMP, WHO, Geneva (GDF site for Anti- TB), TGA Australia (PIC/S), USFDA, UK- MHRA, MCC-South Africa, ISO 9001 and ISO 14001. Spread over hundred acres of land, Cadila Pharmaceuticals’ manufacturing facility at Dholka is the cynosure of all eyes, well equipped with world-class production facilities. The company’s two Active Pharmaceutical Ingredients units at Ankleshwar manufacture a wide-range of APIs and intermediates including three USFDA certified products. The manufacturing facility at Samba, near Jammu, started its commercial operations in August 2006. The first overseas formulation manufacturing facility of Cadila Pharmaceuticals Ltd. has commenced its operations in Ethiopia.

A responsible corporate citizen conscious of its duty towards various sections of the society; Cadila Pharmaceuticals nurtures young talents; runs an ultra-modern charitable hospital in a remote area with facilities like Telemedicine in association with Apollo Ahmedabad; works closely with NGOs by way of assistance and support for mid-day meal programmes, among other initiatives.

Jobs in Cadila Pharmaceuticals Ltd India

Current Openings

Want to sharpen your talent and embrace new opportunities at Cadila Pharmaceuticals Ltd. If so, introduce yourself to us.

Send your resume to careers@cadilapharma.co.in

9.Aventis (Sanofi) Pharma Limited

AventisA world-class pharmaceutical manufacturer

Sanofi India Limited was incorporated in May 1956 under the name Hoechst Fedco Pharma Private Limited. Over the years, its name was changed to Hoechst Pharmaceuticals Private Limited, Hoechst India Limited and Hoechst Marion Roussel Limited.

Sanofi, one of the world’s leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.4% of its paid-up share capital.

The shares of Sanofi India Limited are quoted on the Bombay Stock Exchange (Security Code: 500674) and the National Stock Exchange (Security Code: AVENTIS EQ).

Our activities
Aventis Pharma Limited Products
Aventis Pharma Limited in India provides medicines for the treatment of patients in several therapeutic areas: cardiology, thrombosis, oncology, diabetes, central nervous system, internal medicine and consumer healthcare.

Industrial Affairs

Aventis Pharma Limited has two state-of-the-art manufacturing facilities at Ankleshwar, Gujarat (chemistry and pharmaceuticals) and at Verna, Goa (pharmaceuticals). Incorporating the latest designs and processes in manufacturing, both sites have been identified as global sourcing units.

10.Ipca Laboratories Limited

Profile

For more than 60 years, Ipca has been partnering healthcare globally in over 110 countries and in markets as diverse as Africa, Asia, Australia, Europe and the US.

Ipca is a fully-integrated Indian pharmaceutical company manufacturing over 350 formulations and 80 APIs for various therapeutic segments.

We are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced right from the basic stage at manufacturing facilities endorsed by the world’s most discerning drug regulatory authorities like US-FDA, UK-MHRA, EDQM-Europe, WHO-Geneva and many more.

Ipca is a therapy leader in India for anti-malarials with a market-share of over
34% with a fast expanding presence in the international market as well. We also lead in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for rheumatoid arthritis. We have leading brands in 5 therapeutic areas, with 4 of our branded formulations being ranked among the Top-300 Indian brands by ORG-IMS.

Our international client roster includes global pharmaceutical giants like AstraZeneca, GlaxoSmithKline, Merck, Roche and Sanofi Aventis; most of whom we have been partnering over the years.

At Ipca, quality assurance is an attitude of seeking sustainable betterment in every aspect of our work. The results show in our financials as well as work ethic. Net income for the financial year ended 31st March 2012 was
Rs. 2,342.29 Crores (US$ 486 Mn). Net profit was Rs. 280.17 Crores
(US$ 58 Mn).

What’s more, Ipca was awarded as ‘Among the 100 Best Companies to Work in India 2010’ in a study conducted by Great Place to Work® – India in joint collaboration with The Economic Times.

 

Pharma industry to see lower growth this fiscal: IDMA president

The pharmaceutical industry in the country, which has been recording a growth of around 15% over past few years, would see a lower growth of 10-12% this fiscal year, owing to the current economic slowdown and the new Drug Price Control Order (DPCO), expects the pharmaceutical manufacturers’ association.

With the prospects increasing in exports, the association is planning to tie up with its counterparts in various countries including China, Japan and Britain, said S V Veeramani, who recently took over as the president of Indian Drug Manufacturers’ Association (IDMA).

“The industry has seen a mere growth of one% in August and a negative growth in September, in 2013. However, it bounced back to six% growth in November and nine% in December,” he said. The growth in November and December could also be attributed to the season, which generally see an increase in sales of antibiotics and some of the other medicines as there would be an increase in number of minor health issues due to the climate change.

The industry has seen a growth of 14.9% in 2011 and 16.6% in 2012, he said quoting reports from AIOCD Pharmasofttech AWACS, a pharmaceutical market research company of the traders’ organisation AIOCD. While the industry has seen a recovery from the slowdown, the growth for the financial year would reflect a drop of 2-3%.

The new DPCO has restricted price of 348 essential medicines based on market linked pricing and putting a cap for increase in price based on the wholesale price index of the drugs. According to the report, the industry has seen a loss of Rs 140-150 crore per month in the first couple of months due to this, he said.

However, the country continue to be a good opportunity with the health allocation in budgets going up, increased penetration of insurance and public awareness on importance of health.

The association is also looking at supporting more of its members to start exports, with the opportunities for exports are also growing.  It is entering into tie up with the China Pharmaceutical Industry Association (CPIA), IDMA’s counterpart in China, for collaboration starting with information sharing and interaction and removing bilateral trade frictions.

The tie up could eventually lead companies in both the countries work together, and even getting into joint venture where the strengths of the companies could be used for mutual benefit.  Similar discussions are going on with Osaka Pharmaceutical Manufacturers Association (OPMA) and plans are to start discussions with British Generic Manufacturers Association (BGMA), which represents the interests of UK-based manufacturers and suppliers of generic medicines and promotes the development and understanding of the generic medicines industry in the United Kingdom.

Moderate alcohol consumption helps boost immunity, says study

wine glassA glass of wine a day can help keep the doctor away.

A research group, led by a University of California, Riverside, immunologist, found that moderate alcohol consumption, such as a daily glass of wine, can boost the immune system, potentially helping people fight infections.

The knowledge could be used to improve reactions to vaccines and infections, according to a news release.

For example, even though elderly patients may receive a flu vaccine, it remains relatively ineffective.

Scientists already have found that moderate alcohol consumption has been associated with lower mortality.

Using a dozen rhesus monkeys, the research group studied the effects of alcohol consumption on the immune system.

The monkeys were trained to consume alcohol when they wanted.

The researchers initially vaccinated the animals against small pox. The test group was provided access to either 4 percent ethanol, which has a similar proof to beer, while the control group had access to calorically matched sugar water. Both groups also had access to plain water.

The researchers monitored the animals for 14 months. At month seven, they vaccinated the animals again.

During nine months of the animals’ self-administered alcohol consumption, daily intake varied widely.

Before consuming alcohol, all of the monkeys’ responses to vaccination were similar.

Following alcohol consumption the groups showed markedly different responses after receiving the second, or booster, vaccine.

Similar to human counterparts, monkeys that drank the largest amounts of alcohol had greatly diminished vaccine responses compared to the control group.

But those that drank moderate amounts of alcohol had enhanced vaccine responses.

“These surprising findings indicate that some of the beneficial effects of moderate amounts of alcohol consumption may be manifested through boosting the body’s immune system,” Ilhem Messaoudi, an associate professor of biomedical sciences and lead author, said in the release.

“This supports what has been widely believed for some time: moderate ethanol consumption results in a reduction in all causes of mortality, especially cardiovascular disease. As for excessive alcohol consumption, our study shows that it has a significant negative impact on health.”

– See more at: http://www.thegrower.com/news/Moderate-alcohol-consumption-helps-boost-immunity-says-study-236390111.html#sthash.XMC1tgk8.dpuf

GlaxoSmithKline to spend $1 billion to raise stake in Indian pharma unit

GSK said that it was looking to buy a 24% stake in the pharmaceuticals subsidiary for about $1billion or Rs 6,400 crore.

GlaxoSmithKline Plc (GSK), the UK’s largest drug maker, offered to spend up to $1 billion to raise its stake in Indian subsidiary GlaxoSmithKline Pharmaceuticals LtdBSE 0.64 % through a voluntary open offer, in line with similar moves by other overseas companies and marking its confidence in the local business despite new price controls having sharply eroded sales in the country.

The move will result in GSK investing a total $2 billion dollars or so in its two Indian subsidiaries, ind ..

Indian healthcare sector is set for a turnaround: Devi Shetty

Indian healthcare sector is still in an "embryonic" stage but is set for a turnaround in near future, eminent cardiac surgeon Dr Devi Shetty said.Indian healthcare sector is still in an “embryonic” stage but is set for a turnaround in near future, eminent cardiac surgeon and philanthropist Dr Devi Shetty said here today.

“Indian healthcare system is still in an embryonic stage. But, India will be able to prove to the world that health can be dissociated from affluence. Within five to ten years, every person in India will get access to quality healthcare,” said Shetty, who was the chief g ..

 

Torrent Pharma acquires Elder’s domestic business for Rs 2000 crore

Ahmedbad-based Torrent Pharmaceutical Ltd acquired branded domestic formulation business of Mumbai-headquartered Elder Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

BSE 479.50

-20.20(-4.04%)

Vol: 832896 shares traded

NSE

479.65

Ahmedbad-based Torrent Pharmaceutical Ltd acquired branded domestic formulation business of Mumbai-headquartered Elder Pharmaceuticals Ltd.
Ahmedbad-based Torrent Pharmaceutical LtdBSE -0.74 % acquired branded domestic formulation business of Mumbai-headquartered Elder Pharmaceuticals LtdBSE -8.17 %. The deal size is Rs 2000 crore that include Elder’s domestic formulation businesses of India as well as Nepal.
According to the Torrent Pharma’s statement on Bombay Stock Exchange, Elder’s India Business comprises a portfolio of over 30 brands with market leading products a ..